BJH - volume 9, issue 5, september 2018
C. Bonnet MD, M.C. Ngirabacu , M. Maerevoet MD, V. De Wilde MD, PhD, E. Van den Neste MD, PhD, M. André MD, PhD
The 4th edition of the LYSA meeting was organised by Professor Steven Legouill’s team and held in Nantes from the 8th to 10th February, 2018. It was a real opportunity for the 500 participants to learn novelties on lymphoma and to be updated on ongoing clinical trials conducted by this cooperative group. All the presentations were outstanding and gave us new indications on how to better treat our patients in the near future.
(BELG J HEMATOL 2017;9(5):195–8)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
E. Collinge MD, C. Graux MD, PhD, M. André MD, PhD, H. Labussière-Wallet , M. Michallet , G. Salles
BJH - 2018, issue Abstract Book BHS, february 2018
O. Stas , E. Mourin MD, J. Depaus MD, F-X. Hanin , I. Theate , M. André MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
A. Smet , V. Van Hende MD, M. André MD, PhD, C. Bonnet MD, G. Bries MD, PhD, V. De Wilde MD, PhD, H. Demuynck MD, N. Meuleman MD, PhD, W. Schroyens MD, PhD, A. Van Hoof MD, PhD, M. Giordan , L. de Vos , A. Janssens MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
G. Verhoef MD, PhD, M. André MD, PhD, J. Imschoot , P. Graas , D. Bron MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
S. Bailly MD, M.C. Vekemans MD, B. Chatelain PharmD, M. André MD, PhD, T. Vander Borght , L. D’Hondt , L. Faugeras , G. Verstraete MD, J. Devreux , G. Di Prinzio , S. Lefevre
BJH - volume 7, issue 5, october 2016
P. Mineur MD, C. Doyen MD, N. Straetmans MD, PhD, K. Van Eygen MD, D. Pranger MD, A. Bosly MD, PhD, M. André MD, PhD, T. Devos MD, PhD, L. Knoops MD, PhD, On behalf of the MPN Belgian Hematological Society subcommittee
This article describes the Belgian register of chronic myeloid leukaemia patients who have stopped their treatment with imatinib in conditions comparable to the French STIM trial results: 44% remained in major molecular response off therapy; relapses appear rapidly after stopping imatinib and are responsive when the treatment is resumed.
(BELG J HEMATOL 2016;7(5):184–6)
Read more
Top
